What are the major opportunities in the Plasma Protease C1 Inhibitor market? What are the strategies for the Plasma Protease C1 Inhibitor market?

For detailed insights on the major opportunities and strategies in the Plasma Protease C1 Inhibitor market, Read More

How does the Plasma Protease C1 Inhibitor market relate to the overall economy and other similar markets?

For detailed insights on Plasma Protease C1 Inhibitor's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Plasma Protease C1 Inhibitor market growth? SWOT analysis of the Plasma Protease C1 Inhibitor market.

For detailed insights on the key dynamics influencing the Plasma Protease C1 Inhibitor market growth and SWOT analysis of the Plasma Protease C1 Inhibitor industry, Read More

Global Plasma Protease C1-Inhibitor Market Report 2025

Item added to cart!

Published : December 2025

Pages : 200

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Plasma Protease C1-Inhibitor Global Market Report 2025

Name: Plasma Protease C1-Inhibitor Global Market Report 2025
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

By Drug Class (C1-Inhibitors, C1-Esterase Inhibitor, Recombinant Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist), By Dosage Form (Lyphophlised, Injectables), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Plasma Protease C1-Inhibitor Market?

Plasma protease C1-inhibitors are drugs that inhibit the activity of plasma protease C1 in the complement system. Their primary purpose is to regulate immune responses by preventing excessive activation of the complement cascade and controlling inflammation. They help maintain balance in immune and coagulation pathways to protect tissues from damage.

The main types of drugs that target plasma protease C1-inhibitor are C1-inhibitors, C1-esterase inhibitors, recombinant inhibitors, kallikrein inhibitors, and selective bradykinin B2 receptor antagonists. C1-inhibitors are blood proteins that regulate the complement system, a component of the immune system responsible for defending against infections and inflammation. These drugs are typically available in lyophilized and injectable dosage forms and distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Plasma Protease C1-Inhibitor Market Size and growth rate 2025 to 2029: Graph

What Is The Plasma Protease C1-Inhibitor Market Size 2025 And Growth Rate?

The plasma protease c1-inhibitor market size has grown rapidly in recent years. It will grow from $3.37 billion in 2024 to $3.85 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to increasing prevalence of hereditary angioedema, growing awareness about rare genetic disorders, increasing demand for plasma-derived biologics, growing diagnostic rates for C1-inhibitor deficiency, and increasing adoption of replacement therapy in emergency care.

What Is The Plasma Protease C1-Inhibitor Market Growth Forecast?

The plasma protease c1-inhibitor market size is expected to see rapid growth in the next few years. It will grow to $6.53 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to growing focus on personalized medicine, increasing pipeline developments for C1-inhibitor therapies in clinical trials, growing demand for prophylactic treatment options, rising availability of home-based C1-inhibitor infusion therapies, and increasing awareness of C1-inhibitor deficiencies in surgical settings. Major trends in the forecast period include developing orphan drug applications, developing low-immunogenic variants, integration of genomic tools, integration into telemedicine platforms, and innovation in long-acting C1-inhibitors.

Book your 30 minutes free consultation with our research experts

How Is The Plasma Protease C1-Inhibitor Market Segmented?

The plasma protease c1-inhibitor market covered in this report is segmented –

1) By Drug Class: C1-Inhibitors, C1-Esterase Inhibitor, Recombinant Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist

2) By Dosage Form: Lyphophlised, Injectables

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By C1-Inhibitors: Plasma-Derived C1-Inhibitor, Recombinant C1-Inhibitor

2) By C1-Esterase Inhibitor: Intravenous (IV) C1-Esterase Inhibitor, Subcutaneous (SC) C1-Esterase Inhibitor

3) By Recombinant Inhibitor: Recombinant Human C1-Inhibitor, Recombinant Analog Inhibitor

4) By Kallikrein Inhibitor: Plasma Kallikrein Inhibitor, Oral Kallikrein Inhibitor

5) By Selective Bradykinin B2 Receptor Antagonist: Injectable B2 Receptor Antagonist, Oral B2 Receptor Antagonist

What Is Driving The Plasma Protease C1-Inhibitor Market? Growing Investment In Rare Diseases Fueling The Growth Of The Market Due To Rising Demand For Targeted Therapies And Regulatory Incentives

The growing investment in rare diseases is expected to propel the growth of the plasma protease C1-inhibitor market going forward. A rare disease is a health condition that affects a small percentage of the population, typically fewer than 1 in 2,000 people. These conditions are often chronic and progressive and can be life-threatening or disabling. Investment in rare diseases is primarily due to the growing recognition of unmet medical needs and the potential for high returns through regulatory incentives such as orphan drug designation, market exclusivity, and reduced development costs. Investment in rare diseases drives the development of plasma protease C1-inhibitors by funding research and innovation to address hereditary angioedema and other rare conditions where C1-inhibitor deficiencies cause severe symptoms, thus accelerating the availability of targeted therapies. For instance, in April 2024, according to Global Genes, a US-based nonprofit organization, companies developing drugs for rare diseases raised $7.1 billion in the first quarter of 2024, marking a 307% increase compared to the $1.8 billion raised in the same period in 2023. Therefore, the growing investment in rare diseases is driving the growth of the plasma protease C1-inhibitor market.

Who Are The Major Players In The Global Plasma Protease C1-Inhibitor Market?

Major companies operating in the plasma protease c1-inhibitor market are Takeda Pharmaceutical Company Limited, CSL Behring LLC, Sigma-Aldrich Co. LLC, Octapharma AG, Bio-Techne Corp, Ionis Pharmaceuticals Inc., Sanquin, Biotest AG, BioCryst Pharmaceuticals Inc., Pharming Group N.V., Sino Biological Inc, Cayman Chemical, Enzo Life Sciences Inc, KalVista Pharmaceuticals Inc., Santa Cruz Biotechnology Inc, Pharvaris N.V., Attune Pharmaceuticals Inc., Biorbyt Ltd, Adverum Biotechnologies Inc, Lev Pharmaceuticals.

What Are The Key Trends Of The Global Plasma Protease C1-Inhibitor Market? Innovative Injectable Therapies Advance Treatment For Rare Swelling Disorders

Major companies operating in the plasma protease C1-inhibitor market are focusing on developing advanced products, such as injectable prescription medicines, to ensure fast, effective relief for hereditary angioedema and improve treatment outcomes. Injectable prescription medicines refer to drugs administered by injection that help restore or replace plasma protease C1-inhibitor to regulate inflammation and prevent swelling attacks. For instance, in December 2022, Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical firm, launched CINRYZE in India. CINRYZE is the first injectable FDA-approved C1 esterase inhibitor for prophylactic treatment in patients aged six years and older. It effectively reduces the frequency, severity, and duration of hereditary angioedema (HAE) attacks by increasing plasma levels of C1-INH, which helps prevent excess bradykinin production and controls the swelling associated with the condition.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Plasma Protease C1-Inhibitor Market? Danaher Corporation Acquires Abcam Plc To Boost Life Sciences And Protein Research Capabilities

In December 2023, Danaher Corporation, a US-based conglomerate company, acquired Abcam plc for $5.7 billion. With this acquisition, Danaher aims to strengthen its life sciences portfolio by enhancing its protein research tools and accelerating innovation in disease mapping and drug discovery. Abcam Plc is a UK-based biotechnology company that offers several products related to plasma protease C1-inhibitor.

What Is The Regional Outlook For The Global Plasma Protease C1-Inhibitor Market?

North America was the largest region in the plasma protease C1-inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protease c1-inhibitor market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the plasma protease c1-inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Plasma Protease C1-Inhibitor Market?

The plasma protease C1-inhibitor market consists of sales of berinert, cinryze, haegarda, firazyr, and lcatibant. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Plasma Protease C1-Inhibitor Industry?

The plasma protease C1-inhibitor market research report is one of a series of new reports from The Business Research Company that provides plasma protease C1-inhibitor market statistics, including the plasma protease C1-inhibitor industry's global market size, regional shares, competitors with the plasma protease C1-inhibitor market share, detailed plasma protease C1-inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the plasma protease C1-inhibitor market. This plasma protease C1-inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Author : Abdul Wasay

Plasma Protease C1 Inhibitor Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$3.85 billion
Revenue Forecast In 2034	$6.53 billion
Growth Rate	CAGR of 14.1% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	The plasma protease c1-inhibitor market covered in this report is segmented – 1) By Drug Class: C1-Inhibitors, C1-Esterase Inhibitor, Recombinant Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist 2) By Dosage Form: Lyphophlised, Injectables 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By C1-Inhibitors: Plasma-Derived C1-Inhibitor, Recombinant C1-Inhibitor 2) By C1-Esterase Inhibitor: Intravenous (IV) C1-Esterase Inhibitor, Subcutaneous (SC) C1-Esterase Inhibitor 3) By Recombinant Inhibitor: Recombinant Human C1-Inhibitor, Recombinant Analog Inhibitor 4) By Kallikrein Inhibitor: Plasma Kallikrein Inhibitor, Oral Kallikrein Inhibitor 5) By Selective Bradykinin B2 Receptor Antagonist: Injectable B2 Receptor Antagonist, Oral B2 Receptor Antagonist
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Takeda Pharmaceutical Company Limited, CSL Behring LLC, Sigma-Aldrich Co. LLC, Octapharma AG, Bio-Techne Corp, Ionis Pharmaceuticals Inc., Sanquin, Biotest AG, BioCryst Pharmaceuticals Inc., Pharming Group N.V., Sino Biological Inc, Cayman Chemical, Enzo Life Sciences Inc, KalVista Pharmaceuticals Inc., Santa Cruz Biotechnology Inc, Pharvaris N.V., Attune Pharmaceuticals Inc., Biorbyt Ltd, Adverum Biotechnologies Inc, Lev Pharmaceuticals.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Plasma Protease C1-Inhibitor Market Characteristics

3. Plasma Protease C1-Inhibitor Market Trends And Strategies

4. Plasma Protease C1-Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Plasma Protease C1-Inhibitor Growth Analysis And Strategic Analysis Framework

5.1. Global Plasma Protease C1-Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Plasma Protease C1-Inhibitor Market Growth Rate Analysis

5.4. Global Plasma Protease C1-Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Plasma Protease C1-Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Plasma Protease C1-Inhibitor Total Addressable Market (TAM)

6. Plasma Protease C1-Inhibitor Market Segmentation

6.1. Global Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

C1-Inhibitors

C1-Esterase Inhibitor

Recombinant Inhibitor

Kallikrein Inhibitor

Selective Bradykinin B2 Receptor Antagonist

6.2. Global Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Lyphophlised

Injectables

6.3. Global Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

6.4. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of C1-Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Plasma-Derived C1-Inhibitor

Recombinant C1-Inhibitor

6.5. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of C1-Esterase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Intravenous (IV) C1-Esterase Inhibitor

Subcutaneous (SC) C1-Esterase Inhibitor

6.6. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Recombinant Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Recombinant Human C1-Inhibitor

Recombinant Analog Inhibitor

6.7. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Plasma Kallikrein Inhibitor

Oral Kallikrein Inhibitor

6.8. Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Injectable B2 Receptor Antagonist

Oral B2 Receptor Antagonist

7. Plasma Protease C1-Inhibitor Market Regional And Country Analysis

7.1. Global Plasma Protease C1-Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Plasma Protease C1-Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Plasma Protease C1-Inhibitor Market

8.1. Asia-Pacific Plasma Protease C1-Inhibitor Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Plasma Protease C1-Inhibitor Market

9.1. China Plasma Protease C1-Inhibitor Market Overview

9.2. China Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Plasma Protease C1-Inhibitor Market

10.1. India Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Plasma Protease C1-Inhibitor Market

11.1. Japan Plasma Protease C1-Inhibitor Market Overview

11.2. Japan Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Plasma Protease C1-Inhibitor Market

12.1. Australia Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Plasma Protease C1-Inhibitor Market

13.1. Indonesia Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Plasma Protease C1-Inhibitor Market

14.1. South Korea Plasma Protease C1-Inhibitor Market Overview

14.2. South Korea Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Plasma Protease C1-Inhibitor Market

15.1. Western Europe Plasma Protease C1-Inhibitor Market Overview

15.2. Western Europe Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Plasma Protease C1-Inhibitor Market

16.1. UK Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Plasma Protease C1-Inhibitor Market

17.1. Germany Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Plasma Protease C1-Inhibitor Market

18.1. France Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Plasma Protease C1-Inhibitor Market

19.1. Italy Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Plasma Protease C1-Inhibitor Market

20.1. Spain Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Plasma Protease C1-Inhibitor Market

21.1. Eastern Europe Plasma Protease C1-Inhibitor Market Overview

21.2. Eastern Europe Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Plasma Protease C1-Inhibitor Market

22.1. Russia Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Plasma Protease C1-Inhibitor Market

23.1. North America Plasma Protease C1-Inhibitor Market Overview

23.2. North America Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Plasma Protease C1-Inhibitor Market

24.1. USA Plasma Protease C1-Inhibitor Market Overview

24.2. USA Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Plasma Protease C1-Inhibitor Market

25.1. Canada Plasma Protease C1-Inhibitor Market Overview

25.2. Canada Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Plasma Protease C1-Inhibitor Market

26.1. South America Plasma Protease C1-Inhibitor Market Overview

26.2. South America Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Plasma Protease C1-Inhibitor Market

27.1. Brazil Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Plasma Protease C1-Inhibitor Market

28.1. Middle East Plasma Protease C1-Inhibitor Market Overview

28.2. Middle East Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Plasma Protease C1-Inhibitor Market

29.1. Africa Plasma Protease C1-Inhibitor Market Overview

29.2. Africa Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Plasma Protease C1-Inhibitor Market Competitive Landscape And Company Profiles

30.1. Plasma Protease C1-Inhibitor Market Competitive Landscape

30.2. Plasma Protease C1-Inhibitor Market Company Profiles

30.2.1. Takeda Pharmaceutical Company Limited Overview, Products and Services, Strategy and Financial Analysis

30.2.2. CSL Behring LLC Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Sigma-Aldrich Co. LLC Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Octapharma AG Overview, Products and Services, Strategy and Financial Analysis

30.2.5. Bio-Techne Corp Overview, Products and Services, Strategy and Financial Analysis

31. Plasma Protease C1-Inhibitor Market Other Major And Innovative Companies

31.1. Ionis Pharmaceuticals Inc.

31.2. Sanquin

31.3. Biotest AG

31.4. BioCryst Pharmaceuticals Inc.

31.5. Pharming Group N.V.

31.6. Sino Biological Inc

31.7. Cayman Chemical

31.8. Enzo Life Sciences Inc

31.9. KalVista Pharmaceuticals Inc.

31.10. Santa Cruz Biotechnology Inc

31.11. Pharvaris N.V

31.12. Attune Pharmaceuticals Inc.

31.13. Biorbyt Ltd

31.14. Adverum Biotechnologies Inc

31.15. Lev Pharmaceuticals

32. Global Plasma Protease C1-Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Plasma Protease C1-Inhibitor Market

34. Recent Developments In The Plasma Protease C1-Inhibitor Market

35. Plasma Protease C1-Inhibitor Market High Potential Countries, Segments and Strategies

35.1 Plasma Protease C1-Inhibitor Market In 2029 - Countries Offering Most New Opportunities

35.2 Plasma Protease C1-Inhibitor Market In 2029 - Segments Offering Most New Opportunities

35.3 Plasma Protease C1-Inhibitor Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of C1-Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of C1-Esterase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Recombinant Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Plasma Protease C1-Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Plasma Protease C1-Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: Takeda Pharmaceutical Company Limited Financial Performance

Table 80: CSL Behring LLC Financial Performance

Table 81: Sigma-Aldrich Co. LLC Financial Performance

Table 82: Octapharma AG Financial Performance

Table 83: Bio-Techne Corp Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of C1-Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of C1-Esterase Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Recombinant Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Kallikrein Inhibitor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Plasma Protease C1-Inhibitor Market, Sub-Segmentation Of Selective Bradykinin B2 Receptor Antagonist, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Plasma Protease C1-Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Plasma Protease C1-Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Plasma Protease C1-Inhibitor Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Plasma Protease C1-Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Plasma Protease C1-Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: Takeda Pharmaceutical Company Limited Financial Performance

Figure 80: CSL Behring LLC Financial Performance

Figure 81: Sigma-Aldrich Co. LLC Financial Performance

Figure 82: Octapharma AG Financial Performance

Figure 83: Bio-Techne Corp Financial Performance

From Insight to Impact: Strategic Growth Mapping in the HER2-Positive Breast Cancer Market

Hospital And Nursing Home Probiotics Market Overview 2025: Competitive Shifts, Forecast Models, and Emerging Opportunities

Next-Gen Implantable Cardioverter Defibrillators (ICDs) : Market Forecast, Transformation, and Long-Term Trajectories

Indwelling Catheters Growth Trajectory: Key Forecasts and Strategic Insights

A strategic 2025 report providing key insights, trends and forecasts for the global live attenuated polio vaccine market between 2025–2034.

A 2025 forecast report outlining growth projections, key trends and regulatory landscape of the medicated shampoo market through 2029.

A 2025 strategic report on market size, competitive landscape and expansion strategies in the medications for heart failure market.

Explore strategic insights and forecasts in the global virtual nutrition coach app market, offering competitive benchmarking and market growth trends.

Checkpoint Inhibitors Global Market Report 2025 – By Drug (PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Other Drugs), By Application (Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cance...

Protein Inhibitors Global Market Report 2025 – By Product (Protein Kinase Inhibitors, Monoclonal Antibody, Other Products), By Application (Oncology, Inflammatory Diseases, Other Applications), By Distribution Channel (H...

Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Report 2025 – By Drugs Type (Avastin, Tecentriq, Lucentis, Tagrisso, Cometriq, Eylea, Other Drug Types), By Route Of Administration (Oral, Intravenous, In...

TNF Alpha Inhibitors Global Market Report 2025 – By Drug (Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), Simponi (Golimumab)), By Route Of Administration (Oral, Subcutaneous...

Interleukin Inhibitors Global Market Report 2025 – By Type (IL-17, IL-23, IL-1, IL-5, IL-6, Other Types), By Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Other Ap...

Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2025 – By Product Type (Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars ), By Route Of Administration (Subcutaneous Injection, Intravenous In...

ACE Inhibitors Global Market Report 2025 – By Type (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents), By Drug (Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipri...

Frequently Asked Questions

What is the definition of the Plasma Protease C1 Inhibitor market?

How will the Plasma Protease C1 Inhibitor market drivers and restraints affect the market dynamics? What forces will shape the Plasma Protease C1 Inhibitor industry going forward?

The Plasma Protease C1 Inhibitor market major growth driver - Growing Investment In Rare Diseases Fueling The Growth Of The Market Due To Rising Demand For Targeted Therapies And Regulatory Incentives. For further insights on the Plasma Protease C1 Inhibitor market, request a sample here

What is the forecast market size or the forecast market value of the Plasma Protease C1 Inhibitor market?

The Plasma Protease C1 Inhibitor market size has grown strongly in recent years. The plasma protease c1-inhibitor market size has grown rapidly in recent years. It will grow from $3.37 billion in 2024 to $3.85 billion in 2025 at a compound annual growth rate (CAGR) of 14.4%. The growth in the historic period can be attributed to increasing prevalence of hereditary angioedema, growing awareness about rare genetic disorders, increasing demand for plasma-derived biologics, growing diagnostic rates for C1-inhibitor deficiency, and increasing adoption of replacement therapy in emergency care. The plasma protease c1-inhibitor market size is expected to see rapid growth in the next few years. It will grow to $6.53 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to growing focus on personalized medicine, increasing pipeline developments for C1-inhibitor therapies in clinical trials, growing demand for prophylactic treatment options, rising availability of home-based C1-inhibitor infusion therapies, and increasing awareness of C1-inhibitor deficiencies in surgical settings. Major trends in the forecast period include developing orphan drug applications, developing low-immunogenic variants, integration of genomic tools, integration into telemedicine platforms, and innovation in long-acting C1-inhibitors. For further insights on the Plasma Protease C1 Inhibitor market, request a sample here

How is the Plasma Protease C1 Inhibitor market segmented?

The plasma protease c1-inhibitor market covered in this report is segmented –
1) By Drug Class: C1-Inhibitors, C1-Esterase Inhibitor, Recombinant Inhibitor, Kallikrein Inhibitor, Selective Bradykinin B2 Receptor Antagonist
2) By Dosage Form: Lyphophlised, Injectables
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By C1-Inhibitors: Plasma-Derived C1-Inhibitor, Recombinant C1-Inhibitor
2) By C1-Esterase Inhibitor: Intravenous (IV) C1-Esterase Inhibitor, Subcutaneous (SC) C1-Esterase Inhibitor
3) By Recombinant Inhibitor: Recombinant Human C1-Inhibitor, Recombinant Analog Inhibitor
4) By Kallikrein Inhibitor: Plasma Kallikrein Inhibitor, Oral Kallikrein Inhibitor
5) By Selective Bradykinin B2 Receptor Antagonist: Injectable B2 Receptor Antagonist, Oral B2 Receptor Antagonist For further insights on the Plasma Protease C1 Inhibitor market, request a sample here

Which region has the largest share of the Plasma Protease C1 Inhibitor market? What are the other regions covered in the report?

Who are the major players in the Plasma Protease C1 Inhibitor market?

What are the key trends in the Plasma Protease C1 Inhibitor market?

Major trends in the Plasma Protease C1 Inhibitor market include Innovative Injectable Therapies Advance Treatment For Rare Swelling Disorders. For further insights on the Plasma Protease C1 Inhibitor market, request a sample here.